🇺🇸 FDA
Pipeline program

APO010

APO010/P1/002

Phase 2 small_molecule terminated

Quick answer

APO010 for Relapsed/Refractory Multiple Myeloma is a Phase 2 program (small_molecule) at Allarity Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Allarity Therapeutics
Indication
Relapsed/Refractory Multiple Myeloma
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials